24 February 2023 18:15 GMT

AstraZeneca prices €1.5 billion bond offering

AstraZeneca PLC ("AstraZeneca") announces that, on 24 February 2023, it successfully priced €750 million of fixed rate notes with a coupon of 3.625% maturing on 3 March 2027 and €750 million of fixed rate notes with a coupon of 3.750% maturing on 3 March 2032 (the "Notes").

AstraZeneca expects to use the net proceeds of the offering for general corporate purposes, including refinancing of existing indebtedness.

The Notes will be issued under the US$10,000,000,000 EMTN programme of AstraZeneca and AstraZeneca Finance LLC and admitted to listing on the UK Financial Conduct Authority's Official List and to trading on the London Stock Exchange's Main Market.

The Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC